Candel Therapeutics Inc. (CADL)
Candel Therapeutics Statistics
Share Statistics
Candel Therapeutics has 47.24M shares outstanding. The number of shares has increased by 58.74% in one year.
| Shares Outstanding | 47.24M |
| Shares Change (YoY) | 58.74% |
| Shares Change (QoQ) | 6.21% |
| Owned by Institutions (%) | 56% |
| Shares Floating | 34.58M |
| Failed to Deliver (FTD) Shares | 6.37K |
| FTD / Avg. Volume | 0.51% |
Short Selling Information
The latest short interest is 1.78M, so 4% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short % of Shares Out | 4% |
| Short % of Float | 5.5% |
| Short Ratio (days to cover) | 7.72 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -7.36. Candel Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -7.36 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 4.15 |
| P/FCF Ratio | -10.17 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Candel Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.77 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | -0.33 |
| Debt / FCF | -0.4 |
| Interest Coverage | 15.97 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $0 |
| Employee Count | 38 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -24.88% in the last 52 weeks. The beta is -0.94, so Candel Therapeutics's price volatility has been lower than the market average.
| Beta | -0.94 |
| 52-Week Price Change | -24.88% |
| 50-Day Moving Average | 7.97 |
| 200-Day Moving Average | 6.67 |
| Relative Strength Index (RSI) | 26.53 |
| Average Volume (20 Days) | 1.24M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -33.37M |
| Net Income | 0 |
| EBITDA | -33.37M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.74 |
Balance Sheet
The company has 102.65M in cash and 10.87M in debt, giving a net cash position of 91.79M.
| Cash & Cash Equivalents | 102.65M |
| Total Debt | 10.87M |
| Net Cash | 91.79M |
| Retained Earnings | -192.21M |
| Total Assets | 106.87M |
| Working Capital | 66.28M |
Cash Flow
In the last 12 months, operating cash flow was -27.02M and capital expenditures -16K, giving a free cash flow of -27.04M.
| Operating Cash Flow | -27.02M |
| Capital Expenditures | -16K |
| Free Cash Flow | -27.04M |
| FCF Per Share | -0.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CADL is $22, which is 355.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 355.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 0.26 |
| Piotroski F-Score | 3 |